0001712762
false
DE
0001712762
2023-10-10
2023-10-10
0001712762
BIAF:CommonStockParValue0.007PerShareMember
2023-10-10
2023-10-10
0001712762
BIAF:TradeableWarrantsToPurchaseCommonStockMember
2023-10-10
2023-10-10
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): October 10, 2023
BIOAFFINITY
TECHNOLOGIES, INC.
(Exact
name of registrant as specified in its charter)
Delaware |
|
001-41463 |
|
46-5211056 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
Number) |
|
(I.R.S.
Employer
Identification
Number) |
22211
W Interstate 10
Suite
1206
San
Antonio, Texas
78257
(210)
698-5334
(Address
of principal executive offices and Registrant’s telephone number, including area code)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
|
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c)) |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common
Stock, par value $0.007 per share |
|
BIAF |
|
The
Nasdaq Stock Market LLC |
Tradeable
Warrants to purchase Common Stock |
|
BIAFW |
|
The
Nasdaq Stock Market LLC |
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
7.01. Regulation FD Disclosure.
bioAffinity
Technologies, Inc., a Delaware corporation (the “Company”), will be making several presentations to investors over the next
several weeks. In connection with the presentations, the Company intends to discuss the investor presentation, which is furnished as
Exhibit 99.1 to this Current Report on Form 8-K.
The
information in this Item 7.01, in the investor presentation furnished as Exhibit 99.1 and in the press release furnished
as Exhibit 99.2 to this Current Report on Form
8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise
subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended, and shall not be incorporated
by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date
hereof, regardless of any general incorporation language in such filing.
The
Company’s investor presentation furnished as Exhibit 99.1 to this Current Report on Form 8-K includes “safe harbor”
language pursuant to the Private Securities Litigation Reform Act of 1995, as amended, indicating that certain statements contained therein
are “forward-looking” rather than historical.
On
October 10, 2023, the Company issued a press release regarding the investor presentation and an upcoming conference at which the Company
intends to present such presentation. A copy of the press release is attached as Exhibit 99.2 to this Current Report on Form 8-K.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits
The
following exhibits are furnished with this Current Report on Form 8-K:
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
BIOAFFINITY
TECHNOLOGIES, INC. |
|
|
|
|
By: |
/s/
Maria Zannes |
|
|
Maria
Zannes |
|
|
President
and Chief Executive Officer |
Dated:
October 10, 2023
Exhibit 99.1
![](https://www.sec.gov/Archives/edgar/data/1712762/000149315223036801/ex99-1_001.jpg)
![](https://www.sec.gov/Archives/edgar/data/1712762/000149315223036801/ex99-1_002.jpg)
![](https://www.sec.gov/Archives/edgar/data/1712762/000149315223036801/ex99-1_003.jpg)
![](https://www.sec.gov/Archives/edgar/data/1712762/000149315223036801/ex99-1_004.jpg)
![](https://www.sec.gov/Archives/edgar/data/1712762/000149315223036801/ex99-1_005.jpg)
![](https://www.sec.gov/Archives/edgar/data/1712762/000149315223036801/ex99-1_006.jpg)
![](https://www.sec.gov/Archives/edgar/data/1712762/000149315223036801/ex99-1_007.jpg)
![](https://www.sec.gov/Archives/edgar/data/1712762/000149315223036801/ex99-1_008.jpg)
![](https://www.sec.gov/Archives/edgar/data/1712762/000149315223036801/ex99-1_009.jpg)
![](https://www.sec.gov/Archives/edgar/data/1712762/000149315223036801/ex99-1_010.jpg)
![](https://www.sec.gov/Archives/edgar/data/1712762/000149315223036801/ex99-1_011.jpg)
![](https://www.sec.gov/Archives/edgar/data/1712762/000149315223036801/ex99-1_012.jpg)
![](https://www.sec.gov/Archives/edgar/data/1712762/000149315223036801/ex99-1_013.jpg)
![](https://www.sec.gov/Archives/edgar/data/1712762/000149315223036801/ex99-1_014.jpg)
![](https://www.sec.gov/Archives/edgar/data/1712762/000149315223036801/ex99-1_015.jpg)
![](https://www.sec.gov/Archives/edgar/data/1712762/000149315223036801/ex99-1_016.jpg)
Exhibit
99.2
bioAffinity
Technologies to Present at the 8th Annual
Dawson James Small Cap Growth Conference
CEO
Maria Zannes to hold one-on-one investor meetings and present a corporate update highlighting commercial strategy
SAN
ANTONIO, Texas (Oct. 10, 2023) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company addressing
the need for noninvasive detection of early-stage lung cancer, today announced that Maria Zannes, President and CEO, will be participating
in the 8th Annual Dawson James Small Cap Growth Conference being held on Thursday, Oct. 12, 2023, in Jupiter, Florida.
Ms.
Zannes is scheduled to present a company overview at 9:30 a.m. ET in Track One-Preserve Ballroom C at the Wyndham Grand Jupiter at Harbourside
Place. She will also be holding one-on-one meetings with prospective investors throughout the day.
On
September 19, bioAffinity Technologies announced the acquisition of the clinical laboratory that helped develop and licensed CyPath®
Lung, a noninvasive test for the early detection of lung cancer currently available as a laboratory developed test (LTD). The acquired
laboratory assets are now known as Precision Pathology Laboratory Services, LLC.
“Our
in-depth marketing research for CyPath® Lung has shown that physicians are enthusiastic about using our test. Our market
research has equipped us with a well-documented commercial growth strategy that I look forward to sharing at the Dawson James conference,”
Ms. Zannes said. “Our recent acquisition of Precision Pathology Laboratory Services strengthens our commercial potential with a
large and growing base of physician customers. The acquisition also boosts our R&D capabilities for additional tests under development.
We believe bioAffinity will be able to build on the success of CyPath® Lung to become a leader in diagnostics.”
Event: |
8th
Annual Dawson James Small Cap Growth Conference |
Date: |
Thursday,
October 12, 2023 |
Time: |
9:30
a.m. Eastern Time |
Location: |
Track
One-Preserve Ballroom C, Wyndham Grand Jupiter at Harbourside Place |
Webcast: |
https://wsw.com/webcast/dawson8/biaf/1990152 |
A
webcast of the presentation will be live and archived on the News & Events section of the company website.
About
Dawson James Securities, Inc.
Dawson
James Securities specializes in capital raising for small and microcap public and private growth companies primarily in the Life Science/Health
Care, Technology, Clean Tech and Consumer sectors. We are a full-service investment banking firm with research, institutional and retail
sales, and execution trading and corporate services. By investing the time required to completely understand your business, we can provide
an appropriate capital transaction structure and strategy including direct investment through our independent fund. Our team will assist
in crafting your vision and shaping your message for the capital markets. Headquartered in Boca Raton, Florida, Dawson James is privately
held with offices in New York, Maryland and New Jersey. www.dawsonjames.com
About
bioAffinity Technologies, Inc.
bioAffinity
Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung, and targeted cancer treatment.
The Company’s first product, CyPath® Lung, is a noninvasive test that has shown high sensitivity and specificity
for the detection of early-stage lung cancer. OncoSelect® Therapeutics, LLC, a subsidiary of bioAffinity Technologies,
is advancing its discoveries shown in vitro to kill cancer cells without harm to normal cells. Research and optimization of the Company’s
platform technologies are conducted in its laboratories at The University of Texas at San Antonio. For more information, visit www.bioaffinitytech.com.
Forward-Looking
Statements
This
press release contains certain forward-looking statements within the meaning of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. These statements are identified by the use of the words “could,” “believe,” “anticipate,”
“intend,” “estimate,” “expect,” “may,” “continue,” “predict,”
“potential,” “project” and similar expressions that are intended to identify forward-looking statements and include
statements regarding bioAffinity being able to build on the success of CyPath® Lung to become a leader in diagnostics.
These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release and
are subject to a number of risks and uncertainties, many of which are difficult to predict, that could cause actual results to differ
materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors
that could cause actual results to differ materially from current expectations include, among others, the Company’s ability to
successfully integrate the pathology laboratory acquisition and increase revenue, the Company’s ability to pursue the development
and support the commercialization of its CyPath® Lung test, the Company’s ability to build near and longer-term
value for its Company’s shareholders and the risk factors described in the Company’s Annual Report on Form 10-K for the year
ended December 31, 2022, the Company’s Quarterly Reports on Form 10-Q, the Company’s Current Reports on Form 8-K and subsequent
filings filed with the Securities and Exchange Commission. The information in this release is provided only as of the date of this release,
and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information,
future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events, except
as required by law.
Contacts:
bioAffinity
Technologies
Julie
Anne Overton
Director
of Communications
jao@bioaffinitytech.com
LHA
Investor Relations
Tirth
T. Patel
tpatel@lhai.com
#
# #
v3.23.3
Cover
|
Oct. 10, 2023 |
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Oct. 10, 2023
|
Entity File Number |
001-41463
|
Entity Registrant Name |
BIOAFFINITY
TECHNOLOGIES, INC.
|
Entity Central Index Key |
0001712762
|
Entity Tax Identification Number |
46-5211056
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
22211
W Interstate 10
|
Entity Address, Address Line Two |
Suite
1206
|
Entity Address, City or Town |
San
Antonio
|
Entity Address, State or Province |
TX
|
Entity Address, Postal Zip Code |
78257
|
City Area Code |
(210)
|
Local Phone Number |
698-5334
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Entity Emerging Growth Company |
true
|
Elected Not To Use the Extended Transition Period |
false
|
Common Stock, par value $0.007 per share |
|
Title of 12(b) Security |
Common
Stock, par value $0.007 per share
|
Trading Symbol |
BIAF
|
Security Exchange Name |
NASDAQ
|
Tradeable Warrants to purchase Common Stock |
|
Title of 12(b) Security |
Tradeable
Warrants to purchase Common Stock
|
Trading Symbol |
BIAFW
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=BIAF_CommonStockParValue0.007PerShareMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=BIAF_TradeableWarrantsToPurchaseCommonStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
bioAffinity Technologies (NASDAQ:BIAF)
Historical Stock Chart
From Jun 2024 to Jul 2024
bioAffinity Technologies (NASDAQ:BIAF)
Historical Stock Chart
From Jul 2023 to Jul 2024